酒精性肝病患者血清IL-17水平及其基因-197A/G位点单核苷酸多态性分析*

doi:10.3969/j.issn.1672-5069.2022.01.015

摘要/Abstract

摘要： 目的探讨酒精性肝病(ALD)患者血清白细胞介素-17(IL-17)水平及其基因-197A/G位点单核苷酸多态性的变化。方法 2015年10月～2020年10月我院收治的酒精性脂肪肝患者44例、酒精性肝炎患者40例、酒精性肝硬化患者34例和ALD相关性肝癌患者18例,采用ELISA法检测血清IL-17水平,采用单核苷酸检测试剂盒检测外周血IL-17-197A/G位点基因多态性。结果肝癌患者血清IL-17水平为(8.7±1.4)pg/mL,显著高于酒精性脂肪肝、酒精性肝炎和酒精性肝硬化患者【分别为(3.7±0.3)pg/mL、(4.0±0.6)pg/mL和(6.9±0.8)pg/mL,均P<0.05】;肝癌患者血清ALT、AST、GGT和ALB水平分别为(54.3±13.3)U/L、(53.8±13.7)U/L、(262.2±17.9)U/L和(33.9±13.8)g/L,酒精性肝硬化患者分别为(39.8±8.8)U/L、(40.1±7.2)U/L、(251.1±7.9)U/L和(31.1±2.6)g/L,酒精性肝炎患者分别为(84.0±7.5)U/L、(75.4±6.8)U/L、(245.1±5.6)U/L和(43.1±5.7)g/L,与酒精性脂肪肝患者【分别为(29.5±5.2)U/L、(30.5±7.8)U/L、(142.7±5.2)U/L和(42.7±3.2)g/L,均P<0.05】比,差异显著;肝癌和酒精性肝硬化患者AA基因型分布频率分别为77.9%和64.7%,显著高于酒精性脂肪肝和酒精性肝炎患者(分别为22.7%和27.5%,均P<0.05),A等位基因分布频率分别为83.3%和75.0%,显著高于酒精性脂肪肝和酒精性肝炎患者(分别为26.1%和33.8%,均P<0.05)。结论高水平的血清IL-17可能与ALD病情进展相关,外周血IL-17-197A/G位点AA基因型和A等位基因是ALD发生的易感基因,可能增加酒精性肝硬化甚至肝癌发生的风险。

关键词: 酒精性肝病, 白细胞介素-17, IL-17-197A/G位点, 基因多态性

Abstract: Objective The aim of this study was to investigate serum interleukin-17 (IL-17) levels and the single nucleotide polymorphism (SNP) of its gene at -197A/G locus in patients with alcoholic liver diseases (ALD). Methods 44 patients with alcoholic fatty liver, 40 with alcoholic hepatitis, 34 with alcoholic cirrhosis and 18 with ALD-related liver cancer were recruited in this study between October 2015 and October 2020, and serum IL-17 level was detected by ELISA. The gene polymorphisms at -197A/G locus were detected by single nucleotide test kits. Results Serum IL-17 level in patients with liver cancer was (8.7±1.4) pg/mL, significantly higher than [(3.7±0.3) pg/mL, (4.0±0.6) pg/mL and (6.9±0.8) pg/mL, respectively, P<0.05] in patients with alcoholic fatty liver, alcoholic hepatitis and alcoholic cirrhosis; serum ALT, AST, GGT and ALB levels in patients with liver cancer were (54.3±13.3)U/L,(53.8±13.7)U/L,(262.2±17.9)U/L and (33.9±13.8)g/L, those in patients with alcoholic liver cirrhosis were (39.8±8.8)U/L,(40.1±7.2)U/L, (251.1±7.9)U/L and (31.1±2.6)g/L, in alcoholic hepatitis were (84.0±7.5)U/L,(75.4±6.8)U/L, (245.1±5.6)U/L and (43.1±5.7)g/L, all significantly different compared to(29.5±5.2)U/L,(30.5±7.8)U/L, (142.7±5.2)U/L and (42.7±3.2)g/L, respectively, P<0.05] in patients with alcoholic fatty liver; the distribution frequencies of AA genotype of IL-17 gene at -197A/G locus in patients with liver cancer and alcoholic cirrhosis were 77.9% and 64.7%, significantly higher than 22.7% and 27.5% (P<0.05) in patients with alcoholic fatty liver and alcoholic hepatitis, and the distribution frequencies of A allele in patients with liver cancer and alcoholic cirrhosis were 83.3% and 75.0%, significantly higher than 26.1% and 33.8% (P<0.05) in patients with alcoholic fatty liver and alcoholic hepatitis. Conclusion High serum level of IL-17 might be related with the progression of ALDs and the AA genotype and A allele of IL-17 at -197A/G locus could be the susceptibility genes of patients with ALD, which might increase the risk of alcoholic liver cirrhosis and even liver cancer.

Key words: Alcoholic liver diseases, Interleukin-17, IL-17 gene at -197A/G locus, Gene polymorphism

冯宇, 杜振元, 李艳彬, 刘红. 酒精性肝病患者血清IL-17水平及其基因-197A/G位点单核苷酸多态性分析^*[J]. 实用肝脏病杂志, 2022, 25(1): 58-61.

Feng Yu, Du Zhenyuan, Li Yanbin, et al. Serum IL-17 levels and single nucleotide polymorphism of its gene at -197A/G locus in patients with alcoholic liver diseases[J]. Journal of Practical Hepatology, 2022, 25(1): 58-61.

参考文献

[1] 何胜, 张震. 血清IL-17水平及其基因多态性与HBV感染临床转归之间的关系研究. 实用肝脏病杂志,2018,21(6):855-858.
[2] Ohashi K, Pimienta M, Seki E. Alcoholic liver disease: a current molecular and clinical perspective. Liver Res,2018,2(4):161-172.
[3] Ganne-Carrié N, Chaffaut C, Bourcier V, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol,2018,69(6):1274-1283.
[4] Otete H, Deleuran T, Fleming KM, et al. Hip fracture risk in patients with alcoholic cirrhosis:a population-based study using English and Danish data. J Hepatol,2018,69(3):697-704.
[5] Mellinger JL, Shedden K, Winder GS, et al. The high burden of alcoholic cirrhosis in privately insured persons in the united states. Hepatology,2018,68(3):872-882.
[6] Intagliata NM, Argo CK, Stine JG, et al. Concepts and controversies in haemostasis and thrombosis associated with liver disease: proceedings of the 7th international coagulation in liver disease conference.Thromb Haemost,2018,118(8):1491-1506.
[7] Lin SY, Lin CL, Chen WS, et al. Association between alcoholic cirrhosis and hemorrhagic stroke: a nationwide population-based study. Alcohol Alcohol,2019,54(3):302-309.
[8] 谢万桃,彭慈军,李雄雄, 等.肝细胞癌患者Th17细胞及细胞因子IL-17、IL-6变化的临床意义.中华肝胆外科杂志,2019,25(7):526-530.
[9] Matsumoto R,Dainichi T, Tsuchiya S, et al. Epithelial traf 6 drives IL-17-mediated psoriatic inflammation. JCI Insight,2018,3(15):e121175.
[10] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[11] 黄华佗,王荣,陆玉兰, 等.IL-17A基因rs3819024和rs8193037单核苷酸多态性与缺血性脑卒中的相关性.中华医学遗传学杂志,2018,35(6):883-886.
[12] 张海森,白玉明,靳胜利, 等.白细胞介素-17基因多态性与骨关节炎易感性之间的相关性研究.中华骨科杂志,2016,36(22):1450-1455.
[13] Bär E, Whitney PG, Moor K, et al. IL-17 regulates systemic fungal immunity by controlling the functional competence ofNK cells. Immunity,2014,40(1):117-127.
[14] 李莹,廖宇圣,孙圣斌,等.血清IL-17与IL-17-197A/G位点单核苷酸多态性和乙型病毒性肝炎易感性研究.中华医院感染学杂志,2020,30(11):1647-1650.
[15] Liu X,Guan JH, Jiang BC, et al. Toll-like receptor 2 modulates the balance of regulatory T cells and T helper 17 cells in chronic hepatitis C. Viral Immunol,2016,29(6):322-331.
[16] Reda R, Abbas AA, Mohammed M, et al. The interplay between zinc, vitamin d and, IL-17 in patients with chronic hepatitis C liver disease. J Immunol Res,2015,40(3):288-296.
[17] Wang J, Liu Y,Xie L, et al. Association of IL-17a and IL-17f gene polymorphisms with chronic hepatitis B and hepatitis B virus-related liver cirrhosis in a Chinese population: a case-control study. Clin Res Hepatol Gastroenterol,2016,40(3):288-296.
[18] Bessa AS, Ragab AM, Nassra RA, et al. Expression levels of aldose reductase enzyme, vascular endothelial growth factor, and intercellular adhesion molecule-1 in the anterior lens capsule of diabetic cataract patients. J Cataract Refract Surg,2018,44(12):1431-1435.
[19] Ma HY, Yamamoto G,Xu J, et al. IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol,2020,72(5):946-959.
[20] Lee JH, Shim YR,Seo W, et al. Mitochondrial double-stranded RNA in exosome promotes interleukin-17 production through Toll-like receptor 3 in alcohol-associated liver injury. Hepatology,2020,72(2):609-625.

酒精性肝病患者血清IL-17水平及其基因-197A/G位点单核苷酸多态性分析^*

Serum IL-17 levels and single nucleotide polymorphism of its gene at -197A/G locus in patients with alcoholic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李衍强, 石慧, 王文珊, 林学贤, 王英运. 原发性胆汁性胆管炎患者血浆细胞毒性T淋巴细胞相关蛋白4基因多态性分析[J]. 实用肝脏病杂志, 2021, 24(6): 831-834.
[2]	吴晓枫, 黄怡, 杨如杏, 邓少东, 张静莹, 官成浓, 王颖. 原发性胆汁性肝硬化患者外周血丝氨酸蛋白酶抑制剂A1基因多态性分析^*[J]. 实用肝脏病杂志, 2021, 24(6): 855-858.
[3]	刘丽霞, 林应源, 李华敏, 蔡水苗. 劳拉西泮与奥沙西泮治疗酒精性肝病并发酒精戒断综合征患者临床疗效对比研究[J]. 实用肝脏病杂志, 2021, 24(5): 709-712.
[4]	王兵, 盛海, 卢晨, 程联胜, 龚庆国. 310例中国人基因组干扰素α1/α2基因多态性研究[J]. 实用肝脏病杂志, 2021, 24(1): 14-18.
[5]	陈燕屏, 黄绍强, 邓鑫, 熊超. 硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 67-70.
[6]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[7]	栗红江, 何福亮, 陈来印. 酒精性肝病患者血清LP、LPO、NOS水平和肠道菌群分布变化分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 536-539.
[8]	高朋彬,赵晓彦,王德华,秦浩,孟明辉,张建集,闫双缓,郑欢伟. 慢加急性乙型肝炎肝衰竭患者血清IFN-γ基因多态性分析[J]. 实用肝脏病杂志, 2020, 23(3): 380-383.
[9]	黄橘村, 胡东辉, 张建军, 田德英. 慢病毒介导miR-203过表达对酒精性肝病大鼠肝损伤的保护作用及其机制研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 171-174.
[10]	刘亿军, 段舒馨, 游春芳, 龚科. HFE基因多态性检测判断慢性丙型肝炎患者疾病活动的价值^*[J]. 实用肝脏病杂志, 2020, 23(2): 195-198.
[11]	孙红菊, 王衍颜, 徐丛聪, 赵红. 硫普罗宁联合美他多辛治疗酒精性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 54-57.
[12]	张冰, 解学军. 酒精性肝硬化患者血CTLA-4和PNPLA3基因多态性及其临床意义分析^*[J]. 实用肝脏病杂志, 2020, 23(1): 86-89.
[13]	徐玲, 任锋. 慢性肝病患者肝组织巨噬细胞功能变化研究新进展^*[J]. 实用肝脏病杂志, 2020, 23(1): 145-148.
[14]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[15]	延喜胜, 李伟, 王剑. 酒精性肝病患者血清细胞因子水平和肠道菌群分布变化研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 518-521.